US Stock MarketDetailed Quotes

GERN Geron

Watchlist

3.930
-0.020-0.51%

Close May 3 16:00 ET

3.910
-0.020-0.51%

Post 19:47 ET

2.33BMarket Cap-11558P/E (TTM)

Geron Stock Forum

MangoXXXX

Apr 12 21:53

$Geron(GERN.US)$ 👀

2F KILL CHEATERS

Apr 12 21:18

$Geron(GERN.US)$
ALLR - RENT - ADIL ) 👈 NO SHORT NO WIN 🤩🤩🤩💰🤩🤗😋

102362254

Apr 7 08:52

March P/L Challenge

What did your March P/L look like:
My portfolio faced a downturn in March, particularly with EV stocks, resulting in an unfavorable profit/loss scenario.
Pleasant surprises: Did any unexpected trades pay off?
Despite this setback, I experienced a pleasant surprise as an unconventional venture into a biotech stock $Geron(GERN.US)$ which yielded modest returns, amidst the market chaos.
Next steps for April: What's your plan?
Looking ahead to April, I am adopting a Dollar-Cost Av...

March P/L Challenge: Dive into your P/L Calendar and share your investment success!

Mars Mooo

Mar 17 09:19

Ten stocks with >30% YTD, Top 5 Gainers (15 Mar), and Quick Poll on the Fed interest rate decisions on 20 Mar 2024

Hello Mooers!

A quick recap for the weekend ending March 17, 2024.

Ten stocks with >30% YTD

$Taiwan Semiconductor(TSM.US)$31.71%

$Arm Holdings(ARM.US)$68.97%

$Taylor Devices(TAYD.US)$106.55%

$Digital World Acquisition Corp(DWAC.US)$122.74%

$Phunware(PHUN.US)$158.29%

$MicroStrategy(MSTR.US)$182.19%

$Viking Therapeutics(VKTX.US)$236.16%

$Super Micro Computer(SMCI.US)$276%

$SoundHound AI(SOUN.US)$320.28%...

SlowndEasyTrades

Mar 16 12:58

$Geron(GERN.US)$ biggest mover in .rut 👀ing good here time to set customized alart

Angel Colon

Mar 16 00:42

$Geron(GERN.US)$ What happend here? Im new and getting destroyed :')

Moomoo AI

Mar 15 23:54

Wedbush analysts predict a June approval for the drug, citing 'robust commercial potential.' Stifel analysts concur, estimating a 95% success rate. They foresee discussions shifting to labeling, launch kinetics, and strategic interest, particularly regarding imetelstat's potential exclusivity runway.

Geron's Stock Soars 95% After FDA Advisory Panel Votes in Favor of Blood-disorder Drug

Moomoo AI

Mar 15 22:18

Despite the FDA's concerns about the drug's efficacy and safety, Wedbush analyst Robert Driscoll maintains an Outperform rating on Geron, criticizing the FDA's analyses as 'one-sided and misguided'.